ScienceFLow

What ScienceFLow does

ScienceFlow S.L. is a privately held life sciences venture capital firm founded in 2021 and headquartered in Donostia-San Sebastián, Spain, operating from a second Donostia office on Calle Bergara. The firm invests in early-stage biotechnology companies sourced from major Life Sciences Hubs, evaluating scientific research, intellectual property, and competitive technologies from both scientific and commercial perspectives, with a defined maximum 4-year exit horizon and a focus on technologies addressing unmet needs in high-growth markets.

The core "product" is the ScienceFlow venture capital offering itself: a single dedicated investment vehicle that sources and manages biotech equity stakes rather than a technology platform with modules or APIs. The firm's underlying capability rests on the scientific credentials of its team — six partners, two external PhD advisors, and a three-member scientific team with credentials spanning PhD, PharmD/MBA, and MD/DrPH/MBA — which supports sourcing and diligence of biotech deals across verticals including neurology, ophthalmology, immuno-oncology, CNS, and metabolic disease. There are no proprietary technology systems, software products, or patents disclosed.

ScienceFlow generates returns through equity appreciation in portfolio companies (current portfolio of eight: Nido Biosciences, Astrocyte Pharma, Chimeron, Inspirna, OcuTerra, Elicio, Aardvark Therapeutics, and Therini Bio) rather than through product or service fees. Distribution of investment opportunities to qualified institutional and accredited investors occurs via direct investor relations and professional networks, supported by a corporate website and LinkedIn presence. The firm is independently operated with no disclosed parent company, external institutional ownership, or subsidiary structure.

Name

ScienceFLow

Legal name

ScienceFlow S.L.

Website

https://www.scienceflow.eu

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

ScienceFlow is a Spain-based life sciences venture capital firm founded in 2021 that invests in early-stage biotechnology companies, serving qualified investors seeking biotech exposure through a dedicated fund structure.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Open-End Investment Funds (525910), Other Scientific and Technical Consulting Services (54169)

SIC

Investment Advice (6282)

akta.pro primary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Life sciences venture capital
• Biotechnology investments
• Early-stage biotech funding
• Equity investments
• Venture capital funds

Headquarters

HQ city

Donostia-san Sebastián

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Returns: ScienceFlow generates returns through equity investments in early-stage biotechnology companies. The firm takes equity stakes in portfolio companies and realizes returns upon exit, typically within a 4-year investment horizon. Revenue is derived from capital appreciation and equity value creation in portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

ScienceFlow is a life sciences venture capital firm that invests in early-stage biotechnology companies sourced from leading Life Sciences Hubs. The firm takes equity stakes in portfolio companies, applies scientific and marketing due diligence to evaluate research, intellectual property, and competitive technologies, and operates with a defined maximum exit strategy of 4 years. It offers qualified investors access to curated, scientifically vetted biotechnology investment opportunities.

Product overview

ScienceFlow is a single unified venture capital offering focused exclusively on the life sciences and biotechnology sector. Rather than a platform-plus-modules architecture, ScienceFlow operates as a dedicated investment vehicle that sources and manages investment opportunities in early-stage biotechnology companies. The firm applies a consistent investment strategy leveraging team experience to identify opportunities across biotechnology sectors, with a focus on technologies fulfilling non-covered needs in high-growth markets and a maximum exit timeline of 4 years.

Differentiator

Problem solved

Functional benefit

Products and services

• ScienceFlow Venture Capital Fund A life sciences venture capital fund dedicated to furthering life science discoveries and bringing investment opportunities to qualified investors. The fund focuses on early-stage biotechnology companies from leading Life Sciences Hubs, evaluating scientific research, intellectual property, and competitive technologies from both scientific and marketing perspectives, with a defined maximum exit strategy of 4 years. The offering is intended for qualified institutional and accredited investors.

Quantifiable outcome

• 4-year maximum exit strategy for portfolio companies

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Expansion highlights5 records

Direct peers

• Atlas Venture: Boston-based venture capital firm exclusively focused on early-stage biotech, building new companies from inception. Highly comparable model of dedicated biotech specialization with a capital-efficient, focused approach.
• Ysios Capital: Spain-based venture capital firm specializing exclusively in life sciences and biotech investments, with a similar early-to-growth stage focus and a comparable portfolio approach. Ysios is the most direct peer given its Iberian base and dedicated biotech thesis.
• Forbion: European life sciences venture capital firm investing in early-to-growth stage biotech companies. Comparable as a dedicated life sciences VC with a similar investment philosophy and European geographic footprint.
• Medicxi: European biotech-focused venture capital firm born out of Index Ventures' life sciences practice. Highly comparable as a specialist biotech VC with a focused, science-driven investment approach and a similar fund-of-funds dynamic.

Regional players

• Caixa Capital Risc: Barcelona-based venture capital arm of 'la Caixa' with significant life sciences investing activity. Comparable as a Spain-headquartered VC with biotech exposure and institutional LP backing, though it invests more broadly across sectors.
• Inveready Asset Management: Spain-based alternative asset manager with biotech/healthcare venture capital activity. Comparable as a domestic Spanish VC with life sciences exposure, though operating with broader sector mandates.

Broad incumbents

• OrbiMed: One of the world's largest healthcare-dedicated investment firms with multi-stage, multi-strategy biotech investment activities. Comparable as a life sciences-focused VC, though significantly larger and more diversified across stages and geographies.
• Novo Holdings (Novo Ventures): Copenhagen-based holding company of the Novo Nordisk Foundation with a major biotech venture investment arm. Comparable as a science-driven biotech VC with a long-duration, foundation-backed model, though vastly larger and with broader stage exposure.
• SR One (GlaxoSmithKline): Healthcare-focused venture capital firm with a biotech investment mandate. Comparable as a specialized life sciences investor with scientific due diligence capabilities, though it operates as part of a larger corporate structure.

Others

• DreaVent Capital: Listed as a partner organization on ScienceFlow's website. Comparable as a venture capital collaborator in the Spanish/European life sciences ecosystem, suggesting a strategic relationship rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/scienceflow

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScienceFLow